Losing 30 kilos on Ozempic costs between €1,800 and €3,800 in Spain

Losing 30 kilos on Ozempic: the real price of the weight-loss jab

There's a figure that surprises anyone who thinks Ozempic is the cheap fix for being overweight: losing 30 kilos with semaglutide costs between €1,800 and €3,800 in Spain. The calculation comes from adding up private endocrinologist appointments at around €80 each, blood tests, check-ups and the drug itself, in a process that stretches over 12 to 24 months. The final bill depends not only on the pharmacy, but on how long your body takes to shed the weight and which version of the medication you use.

What nobody disputes is that its main effect is suppressing appetite. People who inject it stop craving pastries and soda, but not because the drug burns them off — they simply don't feel like eating them. The other benefits — improved blood values, blood pressure or glucose — come as a consequence of losing weight, not from any magic action.

Breaking down the cost: consultations, pens and time

With a prescription from Spain's public health system (Seguridad Social), the pre-filled Ozempic pen costs around €75.52 for the 0.25 and 0.5 mg doses, with a reduced patient co-payment. But that's a mirage: the full treatment costs far more than the patient pays. Add the private visit to the endocrinologist — €80 per consultation — the monitoring blood tests, and the repeat pens as the dose goes up. For a 30-kilo target, the real range is around €1,800-3,800.

The classic alternative — a nutritionist, gym three days a week, giving up alcohol and tobacco, cutting carbs — costs nothing in medication, but demands what the injection gives you for free: consistency. That said, anyone who only injects without changing their diet is guaranteed to regain the weight when the money runs out.

The war of data over safety

This is where the debate gets heated. One camp argues that semaglutide has only 2-4 years of studies behind it and its side effects over a decade are uncharted territory; the other replies that the molecule has been studied in humans for more than 14 years and has been in mass clinical use for almost 9 since approval. And underneath it all, the analogy with the elbichito vaccines: those were held to standards that nobody demands of Ozempic. Those who defend the drug respond that with vaccines there was a social obligation; with a cosmetic jab, there isn't.

What almost everyone accepts is that in 10 years we'll see whether the liver, pancreas and kidneys can take the strain. The optimists point to solid data on cardiovascular and renal efficacy at 50 months; the sceptics remind them that doesn't cover the decade.

The paradox of weight loss: the loose skin nobody wants

There's a critical phase the snake-oil sellers don't mention: after losing a lot of weight, the body is left with residual fat and skin around the waist, back, chest, hips and thighs. It can last one or two years, and many people panic by restricting food even further, which only makes things worse and leaves them with saggy skin that can only be fixed with surgery.

The slow route — relearning how to eat and exercising — avoids that mess. But it takes time and willpower, exactly what Ozempic promises to make unnecessary. The awkward question is whether the quick fix, once you stop paying for it, leaves you where you started or in a worse place.

In any case, the drug isn't for shedding a few extra pounds. It's prescribed for people with clinical obesity, or those with a real health problem. Everyone else is funding an expensive whim, with side effects, and a business that has spiralled out of control.